200 related articles for article (PubMed ID: 27026566)
1. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits.
Seledtsova GV; Shishkov AA; Kaschenko EA; Goncharov AG; Gazatova ND; Seledtsov VI
Eur J Dermatol; 2016 Apr; 26(2):138-43. PubMed ID: 27026566
[TBL] [Abstract][Full Text] [Related]
2. Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses.
Seledtsova GV; Shishkov AA; Kaschenko EA; Seledtsov VI
Biomed Pharmacother; 2016 Oct; 83():1247-1252. PubMed ID: 27565847
[TBL] [Abstract][Full Text] [Related]
3. Xenovaccinotherapy for melanoma.
Seledtsov VI; Shishkov AA; Surovtseva MA; Samarin DM; Seledtsova GV; Niza NA; Seledtsov DV
Eur J Dermatol; 2006; 16(6):655-61. PubMed ID: 17229606
[TBL] [Abstract][Full Text] [Related]
4. Xenovaccinotherapy for colorectal cancer.
Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
[TBL] [Abstract][Full Text] [Related]
5. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
6. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
7. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
9. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
11. Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models.
Campion CA; Soden D; Forde PF
BMC Cancer; 2016 Jul; 16():462. PubMed ID: 27412241
[TBL] [Abstract][Full Text] [Related]
12. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
[TBL] [Abstract][Full Text] [Related]
14. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.
Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL
Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418
[TBL] [Abstract][Full Text] [Related]
16. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
17. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
18. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.
Lee P; Wang F; Kuniyoshi J; Rubio V; Stuges T; Groshen S; Gee C; Lau R; Jeffery G; Margolin K; Marty V; Weber J
J Clin Oncol; 2001 Sep; 19(18):3836-47. PubMed ID: 11559721
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]